Partner Jacob Harper spoke with Healthcare Risk Management about how the agencies regulating the healthcare industry could respond to the US Supreme Court’s decision reversing the Chevron doctrine. Jacob said that concern about whether an agency’s determination will be overturned by a court is likely to change the way in which they provide compliance interpretation.
“That that kind of soft interpretation that is really critical for a lot of the things that we do is going to be harder to obtain,” Jacob said. “The forum that that’s going to get decided in now is going to be active litigation in a courtroom, as opposed to calling the agency and seeing what they want and how they want to do things.”